UNITAID, Cipla Announce Agreement To Lower Cost Of Combination HIV Medication

Devex: Deal slashes drug price of 3 in 1 pill for people living with HIV
“…UNITAID and Indian pharmaceutical company CIPLA have entered into an agreement that allows the latter to slash the prices of its drug, Q-TIB, by 30 percent. This means that a person living with HIV will soon have access to a full month’s worth of the drug for only $1.99…” (Ravelo, 6/8).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.